长春高新最新公告：子公司产品银花泌炎灵片新纳入国家基本药物目录

证券之星07-10

长春高新(000661.SZ)公告称，公司控股子公司吉林华康药业股份有限公司的银花泌炎灵片新纳入《国家基本药物目录(2026年版)》，该目录自2026年9月1日起施行。该产品本次新纳入目录对其后续扩大市场覆盖及产品销售将产生积极作用，但短期内对公司业绩不会产生重大影响。

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2650186094?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-10 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650186094","market":"hk","top_or_hot":-1,"title":"长春高新最新公告：子公司产品银花泌炎灵片新纳入国家基本药物目录","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/000661\">长春高新</a>(000661.SZ)公告称，公司控股子公司吉林<a href=\"https://laohu8.com/S/605077\">华康</a>药业股份有限公司的银花泌炎灵片新纳入《国家基本药物目录(2026年版)》，该目录自2026年9月1日起施行。该产品本次新纳入目录对其后续扩大市场覆盖及产品销售将产生积极作用，但短期内对公司业绩不会产生重大影响。</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/58808020260710.png\"/><img src=\"https://static.stockstar.com/etf/15963320260710.png\"/><img src=\"https://static.stockstar.com/etf/51058020260710.png\"/><img src=\"https://static.stockstar.com/etf/51608020260710.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>长春高新最新公告：子公司产品银花泌炎灵片新纳入国家基本药物目录</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n长春高新最新公告：子公司产品银花泌炎灵片新纳入国家基本药物目录\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 17:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026071000031840.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>长春高新(000661.SZ)公告称，公司控股子公司吉林华康药业股份有限公司的银花泌炎灵片新纳入《国家基本药物目录(2026年版)》，该目录自2026年9月1日起施行。该产品本次新纳入目录对其后续扩大市场覆盖及产品销售将产生积极作用，但短期内对公司业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF</p>\n\n<a href=\"https://stock.stockstar.com/RB2026071000031840.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"https://stock.stockstar.com/RB2026071000031840.shtml","article_id":"2650186094","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650186094","pubTimestamp":1783675853,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"长春高新(000661.SZ)公告称，公司控股子公司吉林华康药业股份有限公司的银花泌炎灵片新纳入《国家基本药物目录(2026年版)》，该目录自2026年9月1日起施行。该产品本次新纳入目录对其后续扩大市场覆盖及产品销售将产生积极作用，但短期内对公司业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0046":"生物疫苗","BK0057":"长吉图板块","BK0028":"国家队","000661":"长春高新","BK0075":"新三板","BK0188":"融资融券","BK0239":"医药制造"},"translate_title":"The latest announcement of Changchun High-tech: the subsidiary product Yinhua Miyanling Tablets is newly included in the national essential drug list","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000661":1.5},"content_text":"长春高新(000661.SZ)公告称，公司控股子公司吉林华康药业股份有限公司的银花泌炎灵片新纳入《国家基本药物目录(2026年版)》，该目录自2026年9月1日起施行。该产品本次新纳入目录对其后续扩大市场覆盖及产品销售将产生积极作用，但短期内对公司业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650186094","isCrawlerRequest":true}